Innovation

A New Generation of Potent Adjuvants

Schepens Eye Research Institute
posted on 03/04/2009

Adjuvants such as alum are used in vaccination to promote the immune response. The bacterial-based adjuvants augment antigen-presenting cell activity to enhance the immunogenicity of the vaccine, but such adjuvants cause severe inflammatory reactions. Specific neuropeptides found in the eye modulate innate and adaptive immunity and can be used to promote immunity associated with vaccination and to minimize the side-effects of immunization. The combination of a neuropeptide with an immunogen modifies the immune response to the immunogen according to the specific need: induction or suppression of vaccine induced inflammation or specific cellular immunity. The technology finds applications in vaccination, immunotherapy and in the development of treatments against autoimmune diseases.


Innovation Details
 

File Number: SERI-145 

Other Information:

Investigator(s)
Ph.D. Andrew Taylor

Contact
Mary Chatterton, Director of Corporate Alliances. mary.chatterton@schepens.harvard.edu.


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact the case manager at Schepens Eye Research Institute for more information.

Request more info via email request more info
People

No people are currently associated with this innovation.


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

12,945 members 17,265 innovations 176 organizations

Browse

Alan Thomas, Director, UChicagoTech

"The iBridge Network has opened up new avenues for innovations at UChicagoTech. Relationships between researchers from other universities or industry can be built and strengthened, while investors can find new technologies to advance. "  read more...